Mesa Laboratories Reports 17.5% Revenue Growth in Q3 2025

Mesa Laboratories, Inc. reported strong financial results for its third quarter of fiscal year 2025, ending December 31, 2024, with revenues reaching $62.84 million, a 17.5% increase from the previous year, surpassing analyst estimates. Despite this revenue growth, the company faced a net loss of $1.68 million attributed to foreign currency losses and increased interest expenses. The operating income surged by 8,725% to $5.78 million, reflecting a robust performance, particularly in its Biopharmaceutical Development and Calibration Solutions divisions. Mesa's core organic revenues rose by 13.2%, and the recent acquisition of GKE contributed significantly to this growth. Management remains optimistic about future revenue prospects, supported by strong sales and strategic investments. However, the company’s challenges with foreign currency fluctuations and rising costs could impact future profitability.